Skip to content
OpenCapital
Get started

Protagonist Therapeutics PTGX AU — PP&E (Net)

Similar metrics at other companies

Alcoa logo
AAAU — PP&E (Net)
$2.03B+4.1%
NOVA, Inc. logo
NOVUS — PP&E (Net)
$941M+1.4%
Armstrong World Industries logo
AWIUS — PP&E (Net)
$624.7M+5.1%
Alcoa logo
AAUS — PP&E (Net)
$773M+3.2%
Armstrong World Industries logo
AWICA — PP&E (Net)
$6M+39.5%
NOVA, Inc. logo
NOVOther Countries — PP&E (Net)
$781M+13.0%

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0×0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Protagonist Therapeutics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's au — pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's AU — PP&E (net)?
Protagonist Therapeutics (PTGX) reported AU — PP&E (net) of $40K in Q4 2025.
How has Protagonist Therapeutics's AU — PP&E (net) changed year-over-year?
Protagonist Therapeutics's AU — PP&E (net) decreased by 14.9% year-over-year, from $47K to $40K.
What does AU — PP&E (net) mean?
This metric represents the net book value of tangible assets, such as laboratory equipment, facilities, and infrastructure, located within the Australian geographic segment. It reflects the company's investment in physical capital necessary to support research, development, and operational activities in that region. Monitoring this balance helps investors assess the scale of regional infrastructure and the depreciation profile of assets supporting clinical-stage operations.